QC Laboratories, Inc. Awarded Nadcap Certification for Computed Radiography
19.7.2023 14:59:00 EEST | Business Wire | Press release
QC Laboratories, Inc., a leading nondestructive testing and inspection services company, has announced that it has been awarded Nadcap certification for computed radiography (AC7114/10S) by the Performance Review Institute (PRI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717661945/en/
(Photo: Business Wire)
The Nadcap certification is a highly respected accreditation that recognizes companies that demonstrate exceptional quality and performance in the aerospace industry. QC Laboratories, Inc. has met the rigorous requirements of the Nadcap audit for computed radiography, which includes stringent technical and quality standards, as well as an assessment of the company's personnel, facilities, and processes.
"We are thrilled to have achieved this certification, which reflects our unwavering commitment to providing the highest quality nondestructive testing and inspection services to our customers," said Jose Crespo, General Manager of QC Laboratories, Inc. "With the addition of Nadcap certification for Computed Radiography per ASTM E2033, combined with our powerful 450kV x-ray system, we are better equipped to serve our Nadcap subscriber customers in aerospace & defense, space, and beyond."
Computed radiography is a nondestructive testing method that uses digital imaging technology to produce high-quality images of internal structures and components. This technology enables the detection of defects and discontinuities in materials, such as cracks, porosity, and inclusions, without damaging them.
QC Laboratories, Inc. has had remarkable success in identifying defects in metal additive manufacturing parts using computed radiography. The company has been able to detect defects as small as 25 microns, which is crucial for ensuring the quality and reliability of complex metal parts made from exotic and refractory metals like those used in aircraft and rocket engine components, where high strength and thermodynamics are required.
With the new Nadcap certification for computed radiography (AC7114/10S), QC Laboratories, Inc. is now able to offer computed radiography services that meet the rigorous quality and technical standards of the aerospace industry. This certification further strengthens the company's position as a trusted provider of nondestructive testing and inspection services to customers in a wide range of industries.
About QC Laboratories, Inc.
QC Laboratories, Inc. is a nondestructive testing laboratory in Hollywood, Florida, USA. The company was founded in 1965 and offers various testing services, including nondestructive testing (NDT), chemical processing, and consulting services.
QC Laboratories serves a variety of industries, including aerospace, additive manufacturing, automotive, defense, manufacturing, and consumer products. The laboratory is accredited by the American Society for Nondestructive Testing (ASNT) and is certified by the Federal Aviation Administration (FAA) and Nadcap (Performance Review Institute) for NDT services.
QC Laboratories has a team of experienced nondestructive engineers and technicians using advanced testing equipment and techniques to provide accurate and reliable results. The laboratory is committed to delivering high-quality services and maintaining the highest standards of professionalism and ethics.
For more information about QC Laboratories' new capability for pre-penetrant etching of metal AM parts, please visit www.qclabs.net or contact the laboratory directly.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230717661945/en/
Contact information
Althea Lawson
QC Laboratories, Inc.
Phone: (954) 925-0499
Email: info@qclabs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom